Wonder what Dr. Arrow's take on ORTC is?
Tuesday July 7, 8:15 am Eastern Time
Company Press Release
Wound Care Maturing Into the Fastest-Growing Biotechnology Sector, Analyst Says
LOS ANGELES--(BW HealthWire)--July 7, 1998--Wound care has become ''a major target of biotechnology companies,'' according to an
analyst covering this sector.
The entire wound care biotechnology sector has been broken down, described and rated in a newly released research report.
Alexander K. Arrow, vice president, research at Wedbush Morgan Securities in Los Angeles, has issued a report describing companies
competing in each of 11 different sub-sectors of the wound care market.
The markets include the diabetic foot ulcer market, the severe burn market, the emergency room wound-closing glue market and eight others.
According to the report, each one is serving as a battleground for companies developing competing wound care products
From the rivalry between Organogenesis Inc. [AMEX:ORG - news] and Ortec International over artificial skin for venous ulcers, to the battle
between Closure Medical Corp. [Nasdaq:CLSR - news] and MedLogic Global Corp. over wound closure glues, the report analyzes the relative
strengths and weaknesses of each wound care company.
The report then goes on to rank each company's position in its market according to three parameters: the strength of its product, the stage of its
development and the effectiveness of its distribution system. The report also offers investment recommendations on four companies on the
Wedbush Morgan wound care research list.
Arrow's report highlights and compares a total of 36 companies (28 public and eight private) in this industry segment. The public wound care
companies included are:
Advanced Tissue Sciences (ATIS), BioSpecifics Corp. (BSTC), Carrington Laboratories (CARN), Chiron Corp. (Nasdaq:CHIR - news), Closure
Medical Corp. (CLSR), Cryolife (CRY), Curative Health Services (CURE), Cypros Pharmaceuticals (CYP) and Datascope Corp.
(Nasdaq:DSCP - news).
Also, Derma Sciences (DSCI), Focal (FOCL), Fusion Medical Technologies (FSON), Genzyme Tissue Repair (GENZL), Gliatech (GLIA),
Human Genome Sciences (HGSI), Integra LifeSciences (IART), Johnson & Johnson (JNJ), Kensey Nash (KNSY), Life Medical Sciences
(CHAI), LifeCell Corp. (LIFC).
Also, Lifecore Biomedical (LCBM), Magainin Pharmaceuticals (MAGN), Organogenesis (ORG), Ortec International (ORTC), Perclose (PERC),
ProCyte Corp. (Nasdaq:PRCY - news), Protein Polymer Technologies (PPTI) and Thermogenesis (KOOL).
Larger companies with collaborations in wound care detailed in the report include:
Baxter Healthcare (BAX), Bristol-Myers Squibb (BMS), Johnson & Johnson (JNJ), Novartis (NVTSY), Tyco International (TYC) and 3M Corp.
(MMM).
NOTE TO EDITORS: To find out about receiving a copy of the report, contact a Wedbush Morgan sales representative. Dr. Arrow's office is
213/688-4521.
Contact:
Wedbush Morgan Securities, Los Angeles
Jeffrey C. Showalter, 213/688-4519 |
